Neuron23 names Andrew Yost as chief business officer

California, USA-based clinical stage biotech Neuron2 has appointed Andrew Yost as the company’s chief business officer (CBO).

Mr Yost will be responsible for overseeing Neuron23’s corporate strategy, strategic partnerships and collaborations, and licensing activities. Neuron23 is developing precision medicines designed for genetically defined neurological and immunological diseases

Mr Yost has nearly two decades of experience in strategy and business development and is well-versed in therapeutics development, strategic transactions, operations, and finance. Before joining Neuron23, he served as CBO at TenSixteen Bio, where he oversaw the precision medicine company’s business development, finance, legal, and operations functions. Prior to that, Mr Yost was senior vice president of corporate development at Regenxbio, where he led all business development, strategic transactions, alliance management, and long-range planning, and played a significant role in the company’s initial public offering.